3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
FED
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
25
Leukemia, Lymphocytic, Chronic, B-Cell
17
Lymphoma, Mantle-Cell
15
Lymphoma, Follicular
11
Waldenstrom Macroglobulinemia
9
Lymphoma
8
Lymphoma, B-Cell, Marginal Zone
7
Recurrence
5
Lymphoma, Non-Hodgkin
4
Lymphoma, B-Cell
2
Neoplasms
1
Leukemia, B-Cell
1
Leukemia
1
Intraocular Lymphoma
1
Dendritic Cell Sarcoma, Interdigitating
1
Congenital Abnormalities
1
Interventions
Cyclophosphamide
178
Cytarabine
110
fludarabine phosphate
102
Methotrexate
98
Busulfan
90
Filgrastim
80
Rituximab
72
Peripheral Blood Stem Cell Transplantation
69
Cyclosporine
60
Radiotherapy
57
Etoposide
57
Mycophenolic Acid
56
Antilymphocyte Serum
56
fludarabine
55
Tacrolimus
55
Vincristine
47
Whole-Body Irradiation
44
Melphalan
42
Dexamethasone
39
Granulocyte Colony-Stimulating Factor
38
sargramostim
34
Methylprednisolone
34
Alemtuzumab
34
Daunorubicin
33
Imatinib Mesylate
32
Mercaptopurine
29
Prednisone
27
Idarubicin
26
Doxorubicin
25
Leucovorin
24
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Leukemia
×
zanubrutinib
×
Clear all
NCT06520098
2025-10-14
Benefit VA
VA Office of Research and Development
Phase 2
Recruiting
100 enrolled